Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2023 | MDM2 inhibitors in liposarcoma: evolving landscape and future directions

Robin L. Jones, MBBS, MRCP, MD, Institute of Cancer Research in London, UK, discusses the persistent interest in utilizing MDM2 inhibitors for well and dedifferentiated liposarcoma. Ongoing trials explore various agents targeting MDM2 in this disease, indicating the evolving landscape of treatment options. Prof. Jones emphasizes the exploration of combination schedules in dedifferentiated liposarcoma and the crucial quest for improved predictive markers of treatment response. Identifying the subset of patients most likely to benefit from MDM2 inhibitor treatment is a key focus. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.